Specifically, large-scale prospective studies are needed to evaluate the impact of sclerostin on CKD–MBD and whether sclerostin can be used to monitor treatment response in BMD and cardiovascular disease in KTRs. This evidence concerns the gene SOST and Marchiafava-Bignami disease.